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Summary Lonidamine or 1-[(2, 4-dichlorophenyl) methyl]-lH-indazole-3-carboxylic acid, studied in a battery
of in vitro and in vivo tests currently used for the screening of anti-tumour agents affecting cell division, has
been shown to have a narrow spectrum of anti-tumour activity. The significance of this finding is discussed in
the light of previous investigations suggesting that lonidamine affects mitochondrial function and not cell
replication. Hyperthermia has been shown to sensitize tumour cells to lonidamine. This observation indicates
that in combination with hyperthermia lonidamine has some potential for the treatment of cancer; moreover,
it suggests that hyperthermia might reproduce a metabolic condition occurring in some stages of the disease.
The blood levels corresponding to the anti-tumour action of lonidamine in animals are in the range of those
detected in patients treated with the drug.
Lonidamine or 1-[(2,4-dichlorophenyl)methyl]-1H-
indazole-3-carboxylic acid is the most potent
derivative of a series of indazole carboxylic acids
which originally aroused interest on account of
their anti-spermatogenic activity observed at very
low doses in comparison with those producing
general toxicity (Corsi et al., 1976). It has also been
reported that the potency of anti-spermatogenic
activity varies ten-fold between the different
members of this series without any parallel changes
in their general toxicity (Silvestrini et al., 1978).
Subsequent studies have shown that lonidamine
also possesses embryotoxic (Scorza Barcellona et al.,
1982) and anti-tumour effects (Caputo, 1981;
Silvestrini, 1981). Unlike general toxicity, these
effects show a quantitative correlation with anti-
spermatogenic activity along the different indazole
carboxylic derivatives, suggesting the involvement of
a common mechanism (Silvestrini, 1981).
There is no indication that lonidamine affects cell
division (Heywood et al., 1981). Instead,
ultrastructural and biochemical studies have
suggested that the mitochondria might represent the
primary target for the anti-spermatogenic action
(Floridi et al., 1980; 1981; Silvestrini, 1981). During
spermatogenesis, the mitochondria of germ cells
pass, according to the definition of Hackenbrock
(1966; 1968) from the "orthodox" to the
"condensed" form (Fawcett, 1970; Machado et al.,
1972; De Martino et al., 1979). Condensed
mitochondria have also been described in tumour
cells in some particular experimental conditions
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(Hackenbrock et al., 1971). Hence the hypothesis
that the condensed mitochondria, which represent
an adaptive phenomenon of cell metabolism to high
energy requirements, might represent a specific
target for the action of lonidamine (Silvestrini,
1981). It has also been observed that in germ cells
the inhibition of respiration produced by
lonidamine is accompanied by a compensatory
increase of aerobic glycolysis, whilst in tumour cells
both respiration and aerobic glycolysis are
inhibited, possibly on account of the importance of
mitochondrially-bound hexokinase in these cells
(Floridi et al., 1981a).
This paper reports the effects of lonidamine,
alone or in combination with hyperthermia, on
some tumour-host systems currently used in the
screening of anti-tumour agents. Hyperthermia has
been used both for practical reasons and on the
assumption that it might induce the appearance of
condensed mitochondria which according to earlier
reports could represent the target for the action of
lonidamine. Since literature on this subject is
lacking, the eventual appearance of condensed
mitochondria under the influence of hyperthermia
has been checked with the electron microscope.
Materials and methods
In vitro tests
The in vitro tests were conducted as described by
Geran et al. (1972); cytotoxicity was assayed by cell
enumeration. The most significant points of these
tests were as follows:
Human epidermoid carcinoma cells of the
nasopharynx (KB cells) were maintained in
monolayer culture in Eagle's minimum essential
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medium (MEM)+ 10% calf serum (CS). Control
tubes were required to exhibit growth of at least 6 x
that of baseline tubes. The assay was run for 4 days.
Lonidamine (ACRAF Rome) was dissolved
(400ugml-') in dimethylsulphoxide (DMSO) and
diluted with the medium to obtain the final test
concentrations. 6-mercaptopurine (Sigma, London),
used as positive control, exhibited an active dose
(ED50) of 0.05-0.5 jugml- .
P-388 lymphocytic leukaemia cells were
propagated as a suspension culture in Fischer's
medium + 10% horse serum. Untreated control
tubes were required to exhibit growth 9 x that of
baseline tubes. The assay was run for 2 days.
Lonidamine was dissolved as described above.
Methyl-lomustine (MeCCNU) (ACRAF-Rome),
used as positive control, showed an ED50 of 1.77-
7 gml m'.
HeLa human carcinoma cells were cultured using
Eagle's MEM + 10% CS +0.1% neomycin. The
assay was run for 2 days. Since in this test the
effective concentrations of lonidamine were in the
range of its water solubility, DMSO was avoided. A
0.02% solution of lonidamine was prepared by
adding 18mg of product to 2ml of 0.1MNaOH.
The mixture was heated to 45°C and 5ml of
distilled water were added under stirring until
complete dissolution occurred. Finally, 38ml of
0.1 MNaOH and 0.69g of NaH2PO4H20 were
added and the volume was adjusted to 90ml with
distilled water.
In this test, AF 1312/TS (1-p-chlorobenzyl-lH
indazol-3-carboxylic acid) (ACRAF Rome) was
used as a reference compound. A 0.2% aqueous
solution of AF 1312/TS was prepared by dissolving
190mg of the compound in 45ml of 0.1 MNaOH.
Fifty ml of NaH2PO4 0.1 M was then added. For
both compounds the final pH was 7.3.
In vitro tests with heating
Cells and Culture Conditions Cells from a Chinese
hamster cell line (HA-1) of ovarian origin were
maintained in Eagle's MEM + 15% foetal calfserum
(FCS) and antibiotics; the cultures were maintained
in a humidified incubator in 5% CO2 in air and
routinely checked for mycoplasma. Exponentially
growing cells were used for all experiments; plating
efficiencies were 70-90%. In all experiments, media
were exchanged just prior to the exposure of cells to
either heat or drug. After such exposure, the
monolayers of cells were rinsed at least twice with
phosphate-buffered saline (PBS). Cells were then
trypsinized and plated at appropriate dilutions for
colony formation. Cell survival was assayed by the
cloning technique of Puck & Marcus (1956).
Heating Monolayers of cells on plastic petri
dishes were exposed to elevated temperatures in
purpose-built hot water baths in incubators. The
pH of the media overlaying the cells was
maintained by a regulated gas flow of a mixture of
5% CO2 in air to values 7.2-7.4. The temperature
was maintained to 43°C+0.1°C; the time required
to reach equilibrium was about 3min and was
included in the quoted heating times. The duration
of heating was varied in steps of 1 h. Lonidamine
and AF 1312/TS were dissolved in DMSO; the
concentrations are given in Table 2. Cells were
exposed to drugs 1 h before and during heating. In
all experiments, media were renewed prior to the
exposure of cells to either heat or drug.
In vivo tests
Unless otherwise indicated, the tests were performed
according to the procedures outlined in the NCI
Protocols for Screening of Anti-Cancer Compounds
(Geran et al., 1972).
The Median Survival Time (MST) was calculated
according to the following formula proposed by the
National Cancer Institute (Instruction 14, Screening
Data Summary Interpretation and Outline of
Current Screen, revised April 1977):
L+cjI/fm
where:
L=lower boundary of class containing median
animal,
=DM-0.5 where: DM = that day when total
deaths) A
A initial animal count+ 1
2
c =class interval = 1 (Day)
j=number of deaths needed to reach median
animal from lower class boundary
fm=frequency of class; i.e., total deaths on DM
Survival was statistically analysed using a
Wilcoxon non-parametric test.
Tests were performed on animals of both sexes;
since no difference was observed between male and
female animals, the results were pooled. The most
significant points of these protoc6ls were as follows:
P-388 lymphocytic leukaemia cells were
propagated as ascites in DBA/2 mice. Tumour cells
were adjusted to 106 cells and implanted i.p. Mice
were randomized by cages. Treatment was given
p.o. or i.p. once daily for 9 days. Data were
calculated as MST. Deaths were recorded daily
until all were dead. The compound was suspended
in 0.3% hydroxypropyl cellulose and the
concentration was adjusted to 10mlkg- body
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L-1210 lymphoid leukaemia cells were
propagated as ascites in DBA/2 and CDF, mice.
Tumour cells were adjusted to 105 cells and
implanted i.p.
The melanotic melanoma B-16 was propagated as
a tumour homogenate (1 g of tumour with lOml of
BSS) in DBF1 mice. The homogenate (0.5 ml) was
injected i.p.
The ependymoblastoma is a mutant subline of an
original methylcholanthrene-induced tumour. A
1 mm3 tumour fragment was implanted
intracranially in B6C3F1 mice by trocar. Treatment
was for 5 days.
Lewis lung carcinoma was propagated by s.c.
implantation of an 8mm3 tumour fragment in the
axillary region of BDF1 mice. Treatment was given
daily for 9 days p.o., i.p. or in the form of
medicated diet. In the latter case, the animals were
housed individually and food consumption was
determined daily.
The Ehrlich ascites was studied in CF1 mice.
Tumour cells were adjusted to 6 x 106 and
implanted i.p. Treatment was administered as
described for the Lewis Lung tumour.
Sarcoma 180 (S180) was propagated in the ascitic
form in CF1 mice. Tumour cells were adjusted to
6 x 106 and implanted i.p. Experiments were also
performed with the solid form of S180. A fragment
of 40mg was implanted s.c. into the dorsum. Unless
otherwise indicated, S180 will refer to the ascitic
form of this tumour.
Among the S180 and Ehrlich ascites recipients,
there was a small percentage of tumour-free
animals. Since they were equally distributed in the
control and treated animals it was decided
aebitrarily not to include these animals in the
analyses. The animals were observed for 3 months
or until death.
Serum and ascites concentrations oflonidamine
Concentrations of lonidamine in serum and ascites
were determined according to the method of
Catanese et al. (1978). The compound was extracted
with n-heptane. Fluorimetric assay was performed
using excitation and emission wavelengths of 305
and 345 nm respectively (uncorrected values). The
sensitivity of the method was 1jigml-' serum or
ascites. The identity of diclondazolic acid was
checked by thin layer chromatography, using a
method applied to AF 1312/TS (Burberi et al.,
1975).
In vivo tests with heating
Experiments were performed on S180- or Ehrlich
ascites-bearing mice, implanted as described above.
Heating was commenced 3 days following
implantation of tumours essentially as described by
Cioli & Silvestrini (1971). Mice were kept in an air-
conditioned cabinet at 39+0.5°C for 7h a day for 4
days. Rectal temperature was checked daily 4h after
initiating the heating session. During each heating
session lonidamine was administered immediately
after optimization of body temperature. Controls
and animals treated with lonidamine only were kept
at 22+1°C. Animals which died during heating or
during the following 3 days were not considered,
since their number was equally distributed among
the various groups.
Ultrastructural observations
Ehrlich ascites-bearing mice were treated for 1 day
only with either heating or lonidamine alone or
with a combination of the two according to the
above procedure. The Ehrlich ascites tumour cells
were withdrawn at the end of heating. The controls
were tumour cells from untreated animals.
The cells were fixed in PAF solution (Zamboni &
De Martino, 1967) containing 2.5% of
glutaraldehyde. After post-fixation in unbuffered
osmium tetroxide the cells were dehydrated and
embedded in Epon 812. This sections were stained
with uranyl acetate and lead hydroxide and
examined on a Siemens Elmiskop 101 electron
microscope.
Results
In vitro tests
Table I summarizes the effects of lonidamine, AF
1312/TS and reference compounds on KB, P-388
and HeLa cells.
Lonidamine produced no decrease in KB tumour
cell growth in the concentration range from 1-
10gml-1 but was effective at 100ugml-'; 6-
mercaptopurine, used as a positive control, was
effective from 1 jigml-1.
The effects of lonidamine in the P-388 test were
similar to those observed with the KB cells.
MeCCNU, used as a positive control was effective
at 10jgml-. In the HeLa test, lonidamine
decreased tumour cell growth at 10jugml- . AF
1312/TS was active at concentrations 2.5 x greater
than lonidamine, i.e. at 25jgml-'.
In vitro tests with heating
Table II shows the effects of lonidamine and AF
1312/TS on survival of Chinese hamster cells (HA-1)
heated at 430C.
These results clearly show that in the presence of
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Table I Effects of lonidamine and reference drugs on
different tumour systems in vitro
Test Concentration Per cent reduction
Tumour substance (ugml ') ofcell growth')
KB Lonidamine 1 6.2
10 2.5
100 73.8
6-mercapto- 1 86.2
purine 10 90.5
100 118.0
P-388 Lonidamine 1 0.0
10 3.9
100 76.5
MeCCNU 1 2.5
10 66.5
100 74.4
HeLa Lonidamine 2.5 9.1
5 9.1
10 55.9
AF 1312/TS 12.5 2.6
25 45.5
50 48.1
100 56.0
a)% reduction calculated as final cell concentration of test
group divided by 96h (KB cells) or 48h (P-388 and HeLa
cells) control concentration.
appreciable increase in the cytotoxicity resulting
from heat. According to results not reported in the
Table, lonidamine per se did not affect plating
efficiencies up to 50pgml- 1. Later experiments,
carried out with the lysine salt of lonidamine and in
the absence of DMSO showed much reduced
hyperthermic sensitization. This suggests that
DMSO facilitates entry of the drug into the cells.
AF 1312/TS, up to the maximum concentration
used (50pgml-') did not increase the sensitivity of
the cells to hyperthermia.
In vivo tests
Lonidamine in a dose range 50-200mgkg-1 i.p. or
50-400mgkg-' p.o. did not increase the life span of
mice with P-388, L-1210, B-16 or
ependymoblastoma tumours; at the highest doses
used occasional toxic effects were observed. The
lack of positive results on these tumours was
demonstrated when lonidamine was administered to
groups of 10-32 animals for each dose.
Table III summarizes the results of experi-
ments conducted with the Lewis Lung tumour.
Anti-tumour activity was suggested in the
experiments in which treatment was given i.p. In the
first experiment, an increased life span of 32% was
observed in the group treated with 50mgkg-' i.p.
In the second, the increase of life span was 92% at
the dose, 50mgkg- i.p. and 106% at the dose,
Table II Effects of lonidamine and AF 1312/TS on survival of
Chinese hamster cells (HA-1) heated at 43°C in vitro
DMSO Duration of
Concentration (% of heat exposure Survival
Drug (pgml 1) medium) (h) fraction
Control 0 0 2 10 1
Lonidamine 5 0.1 2 2 x 10-2
AF 1312/TS 5 0.1 2 2x10-
Control 0 1.0 2 3x10-2
Lonidamine 50 1.0 2 10-4
AF 1312/TS 50 1.0 2 4x10-2
Control 0 0.1 3 5 x 10-3
Lonidamine 5 0.1 3 6x 10-5
AF 1312/TS 5 0.1 3 3x10-3
Control 0 1.0 3 5 x 10-5
Lonidamine 50 1.0 3 < 10-s
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Table III Effects of lonidamine on Lewis Lung tumour
in mice(a)
Daily dose (mgkg-1) MST(b)
and route- (day) T/CC(c) ILS0(d)
0 19.0
50 p.o. 19.0 100
100 p.o. 16.3 86
200 p.o. 20.0 105 5
400 p.o. 7.0 41
0 16.1
50 i.p. 21.3 132 32(f)
100 i.p. 19.0 118 18
0 17.3
50 i.p. 33.3 192 92(9)
100 i.p. 35.8 206 106(9)
0 32.0
100 medic. diet (0.08%)0 31.3 97
(a)10 mice were used for each dose.
(b)Median survival time.
(C)MST of test group/MST of 0 dose group x 100.
(')Increased life span.
(e)Lonidamine concentration.
(f)P<0.05.
WP<0.001.
100mgkg-' i.p. Administration by both gavage and
medicated diet gave negative results.
Table IV summarizes the results of experiments
performed with Ehrlich ascites.
Nine days treatment at 50mgkg-' p.o. daily
produced a 25% increase in life span which was not
significant; no effect was observed with 100mgkg-1
p.o. daily. Fifteen days treatment at 100mgkg-'
p.o. daily, decreased the life span. Lonidamine was
inactive when given in the medicated diet.
Table 5 summarizes the results of experiments
performed with S180.
A 22% increase of life span was observed with
25mgkg- 1 p.o. of lonidamine. This value was lower
than the one considered indicative of anti-tumour
action (Geran et al., 1972) and was not statistically
significant. This was supported by the lack of effect
at 50 and l00mgkg-I p.o. These doses are much
lower than those producing general toxicity (see
Table III).
Administration of lonidamine in the diet resulted
in a dose-related increase in life span. AF 1312/TS
was as active as lonidamine at 10 x the dose, i.e.
1250mgkg-' compared with 125mgkg-1
lonidamine in the diet. Using the S180 in the solid
form the efficacy of lonidamine was confirmed.
Serum and ascites concentrations oflonidamine
Lonidamine was measured in the serum of normal
and S180-bearing animals following exposures of
different duration via the diet. In tumour-bearers,
Table IV Effects oflonidamine on the Ehrlich ascites tumour in mice
Daily dose (mgkg-1) No. Days of MST(a)
and route mice treatment (day) TIC%(b) ILS%(c)
0 19 1-9 23.2
25p.o. 20 1-9 25.3 109 9
50 p.o. 18 1-9 29.2 125 25
100 p.o. 18 1-9 22.4 96
0 10 1-15 19.2
100 p.o. 10 1-15 12.2 64
0 18 19.4
250 medic
diet (0.17%)d 19 0-death 21.2 109 9
0 28 22.4
600 medic.
diet (0.33%) 29 0-6 18.4 82.3
(a)Median survival time. (b)MST of test group/MST of 0 dose group x 100. Wc)Increased life span.
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Table V Effects of lonidamine and AF 1312/TS on S180 in mice. Unless
otherwise indicated the tumour was in the ascitic form
Daily dose
Test (mgkg-') No. Days of MST(a)
Substance and route mice treatment (day) T/C%(b) ILS%(c)
Lonidamine 0 19 1-9 22.4
25 p.o. 20 1-9 27.4 122 22
50 p.o. 15 1-9 22.0 98
100 p.o. 19 1-9 24.4 109 9
0 20 20.3
62 medic.
diet (0.04%)e 19 0-death 21.1 104 4
0 37 21.2
125 medic.
diet (0.00%) 37 0-death 26.3 124 24(f)
0 30 23.3
250 medic.
diet (0.17%) 29 0-death 35.3 151 51(g)
0 21 54 (d)
125 medic.
diet (0.08%) 19 0-death 72.5(d) 133 33(h)
AF 1312/TS 0 30 23.3
1250 medic.
diet (0.8%) 30 0-death 29.3 126 26(f)
(a)Median survival time. (b)MST of test group/MST of 0 dose group x 100.
(C)Increased life span. (d)S180 in the solid form. (e)Lonidamine concentration
in parentheses. (f)p<0.01. (u)p<0.001. (h)p<0.05.
treatment was commenced concomitantly with
tumour implantation. The daily doses of 125 and
250mgkg-1 correspond to those which in the
previous experiments produced a significant
increase in life span. The results are summarized in
Table VI.
In tumour bearers, these doses produced serum
concentrations in the range of 12-22 and 18-
28 ugml-1 respectively; similar concentrations were
found in the ascitic fluid. During the first week of
treatment the serum concentrations were higher in
normal animals than in tumour-bearers; no
appreciable difference was observed the following
week. Body fluid levels of lonidamine were also
estimated in mice with Ehrlich ascites which, in the
previously described experiments, proved to be
resistant to lonidamine. The drug was given in the
diet at a daily dose of 250mgkg-' (0.17%). The
animals were killed and examined after 7 days of
treatment. The concentrations were 17.9+1.61 and
22.3+2.14pgml-' in the serum and ascitic fluid
respectively.
In vivo tests with heating
Table VII summarizes the effects of lonidamine
and heating, both alone and together, on S180 and
Ehrlich ascites in mice. Treatments were performed
daily on days 3-6 following tumour implantation.
Lonidamine alone at the daily dose of 50mgkg-
p.o., had no effect on S180. Combination with heat
resulted in a 29% increase in life span.
Lonidamine at the daily dose of 25 or 50mgkg- 1
p.o. did not significantly increase the life span ofLONIDAMINE AND HYPERTHERMIA IN MURINE TUMOUR MODELS 227
Table VI Concentrations of lonidamine in the serum of normal and
S180-bearing mice following dietary administration
igml-1 on days
Daily dose(a) Fluid
Animals (mgkg') examined 3 6 7 12 14
Normal 62 serum 16.7 12.1 14.1
mice +1.17 +0.51 ±0.13
125 serum 32.5 23.1 20.2
±2.02 ±2.59 ±3.15
S180-
bearing 125 serum 22.3 12.2 20.7
mice ±1.48 ±0.76 +3.05
ascites 11.3 17.9(b)
± 1.32
250 serum 27.8 18.1 19.4
± 1.45 ±2.53 ± 1.56
ascites 21.1 19.9
±2.85 ±0.85
(a)The doses given correspond to drug concentrations of 0.04, 0.08
and 0.17%, respectively. For each time and dose level 3 or more
animals were used. (")Studied in one mouse only.
Table VII Effects oflonidamine and heating (39°C) on S180 and Ehrlich ascites tumour in mice
Dailydoseof
lonidamine No. Bodytemp.(b) MST(')
Tumour 7Reatment(a) (mgkg- p.o.) mice (°C;mean±se) (day) T/C%(d) ILS(e)
S180 control 0 16 37.8±0.18 24.3
lonidamine 50 15 38.0±0.13 24.1 99
heating 0 12 39.6±0.15 26.3 109 9
heating+
lonidamine 50 17 39.4±0.08 31.3 129 29(f)
Ehrlich control 16 37.0±0.26 18.3
ascites lonidamine 25 15 36.9+0.18 19.9 109 9
heating 16 39.0±0.12 20.4 111 11
heating+
lonidamine 25 18 39.0±0.12 23.2 127 27(f)
control 15 36.9+0.20 20.2
lonidamine 50 18 37.2±0.16 22.2 110 10
heating 17 39.1 ±0.10 23.3 115 15
heating+
lonidamine 50 17 39.0±0.12 27.4 135 35()
.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
(a)On days 3-6; (b)Average of 4 daily determinations; (c)Median survival time; (d)MST of test
group/MST of 0 dose group x 100; (')Increased Life Span; (f)P<0.05; (1)P<0.001.228 B. SILVESTRINI, G.M. HAHN, V. CIOLI & C. DE MARTINO
animals bearing Ehrlich ascites. Heating was
likewise without any significant effect. Together the
2 treatments resulted in an increase of life span of
27 and 35%, at doses of 25 and 50mgkg-' p.o.
lonidamine respectively.
Ultrastructural observations
Two main types of Ehrlich ascites tumour cells were
visible in the untreated controls. The first type was
more numerous and characterized by mitochondria
with lamellar cristae (Figure 1), regularly arranged
(orthodox form); the second type revealed
mitochondria with dense matrix and expanded
intercristal space (Figure 2) or condensed-like form
(De Martino et al., 1981). In the animals treated
with lonidamine only (50mgkg-' p.o.) there was no
increase in the number of ascitic cells of the second
type, but heating increased their number. In many
cells, several mitochondria assume an unusual form
of condensation (Figure 3). The combination of
lonidamine (50mgkg-1p.o.) with heating induced
severe mitochondrial damage such as rarefaction of
the matrix and disruption of the cristae in
numerous tumour cells (Figure 4).
Discussion
These experiments provide data on three issues
which will be discussed separately: (i) the narrow
spectrum of activity of lonidamine in the battery of
tests currently used for the screening of anti-tumour
agents; (ii) its anti-tumour activity in combination
with hyperthermia; (iii) the blood levels
corresponding to anti-tumour activity in a specific
bioassay relative to those found in man (Besner et
al., 1981 unpublished).
(i) The tumour systems currently used for the
screening of anti-tumour agents differ sharply from
naturally-occurring neoplasms; not only are they
based upon transplantable tumours, but the
tumour-host relationship (which seemingly
influences the course of natural diseases) is altered.
Responsiveness to currently available anti-tumour
agents has been the principal, if not the only,
criterion for the choice of these systems (Gellhorn &
Hirschberg, 1955; Goldin et al., 1966; Wood, 1977).
There are however, some evident limitations
attached to this policy of screening anti-tumour
agents. Most of the presently available agents are
similar in their basic mechanism of action, viz., they
are anti-mitotics. Consequently, screening focuses
on a specialized type of anti-tumour activity, and
there is no evidence that it will eventually identify
agents which act by different mechanisms. Such
might be the case with lonidamine. All the available
data indicate that this drug primarily affects the
energy metabolism (and not the replicative process)
of the cancer cell and this should be taken into
Figure 1 Detail of cytoplasm of Ehrlich ascites tumour cell from untreated animal showing typical orthodox
mitochondria with lamellar cristae ( x 35,000).Figure 2 Detail of cytoplasm of Ehrlich ascites tumour cell from untreated animal showing mitochondria
with dense matrix and expanded intercristal space (condensed form) ( x 35,000).
Figure 3 Tumour cells from heated animals (duration
of treatment, 1 day). In several cells mitochondria are
extremely condensed. Some show unusual arrangement
of the cristae and matrix (arrowed) ( x 20,000).
Figure 4 Tumour cells from animals which received
lonidamine (50mgkg- p.o.) plus heat treatment (1 day
only). The mitochondria of some cells appear swollen
with loss of the matrix and derangement of the cristae
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account when interpreting the results of this study.
Thus, they do not necessarily indicate that
lonidamine is a narrow spectrum anti-tumour agent,
but rather that current experimental tumour models
are unsuitable for the study of drugs acting on the
energy metabolism of the cell.
(ii) The study of hyperthermia relates to both the
problem of the mechanism of action of lonidamine
and its potential therapeutic interest in combination
with hyperthermia. As stated in the Introduction,
previous studies indicate that the condensed
mitochondrion is the target for the activity of
lonidamine (Floridi et al., 1980; 1981; Silvestrini,
1981). Hyperthermia was studied on the basis of the
speculation that it could produce an imbalance
between energy requirements and the oxygen supply
of the tumour cells, thus leading to the formation of
condensed mitochondria. This has been
corroborated here by ultrastructural observations
showing the appearance of condensed mitochondria
under the influence of hyperthermia. The finding
that a degree of hyperthermia, inactive alone, has
significant anti-tumour activity when combined with
lonidamine is in agreement with the working
hypothesis that the state of the energy metabolism
of the cell is the critical factor for the activity of
lonidamine, but is not conclusive. The question
whether hyperthermia reproduces a metabolic state
in experimental tumours which also occurs in some
stages of naturally-occurring tumours is of practical
importance, but cannot be answered by data
presently available. Apart from these theoretical
considerations, our data suggest a potential use of
the lonidamine-hyperthermia combination in the
treatment of cancer. A recent study (Kim et al.,
1982) has confirmed that lonidamine potentiates the
anti-tumour activity of hyperthermia both in vivo
and in vitro, showing that in vitro pH represents a
critical factor for this phenomenon.
(iii) The doses of lonidamine active on S180 have
been shown to correspond to blood concentrations
in the range of 12-28ygml-1; since these blood
levels are in the range of those detected in patients
treated with lonidamine (Besner et al., 1981
unpublished), these results further stress the
potential of lonidamine for the treatment of cancer.
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